With a focus on recruiting, developing, retaining and performing, our
equality, diversity & inclusion strategy enables us to raise the
bar and continue growing. It includes driving awareness and
understanding, attracting and sourcing talent, developing and engaging
talent, and creating connections and community. Learn more
Since our inception in 2013, AbbVie and the AbbVie Foundation have
invested more than $120 million in philanthropic programs that
purposefully support diverse communities.
- We are addressing the achievement gap in our partnerships with Communities In Schools,
City Year and the University of Chicago Education Lab, who are
working to improve graduation rates, reduce dropout rates and boost
college and career readiness for K-12.
- Through our employee
volunteers and our donations, we’ve built school libraries across
the U.S., processed and donated thousands of books, and increased
access to STEM education.
- And in North Chicago, we’re
building a brand-new middle school with a
21st century learning environment to improve student
On June 16, 2020, we made a donation of $5 million to NAACP
Legal Defense and Education Fund and the Equal Justice Initiative to
address issues in our criminal justice system and made an additional
commitment of $50 million in a five-year program to support
underserved Black communities across the United States.
On December 9, 2020, we shared the nonprofit partners part of the
$50 million investment. AbbVie will collaborate with these partners to
support health and education opportunity in underserved Black communities.
AbbVie’s partners are:
Direct Relief to support the improvement of health care
services at free and charitable clinics and federally qualified
health centers (FQHCs). AbbVie’s support will launch the “Fund for
Health Equity,” which will improve care across the country in
undeserved Black communities.
Urban Health Initiative (UHI), the University of Chicago
Medicine’s community health department, to empower Chicago’s South
Side community—made up of 77 percent Black residents— to advance
health equity. AbbVie’s support will enable local teams of community
health workers to promote access to care and resources proven to
measurably reduce health disparities.
National Urban League’s Project Ready Mentor, to
lead a mentorship program for Black Americans and
other historically underserved youth (ages 11-18). AbbVie’s funding
will provide mentorship in three new cities and expand existing
programs in 11 cities to improve post-secondary success.
UNCF Healthcare Diversity Workforce Program, as
seed funding to reduce barriers to advancement in health professions
and increase the number of Black professionals in a wide variety of
health care careers. Scholarship, academic and career development
support will be provided to students who are interested in a career
in health care, but who might otherwise not have an opportunity to
go beyond high school.
Providence St. Mel School to fund scholarships for high
school students living in Chicago’s Southwest side based on
financial need and academic potential. This independent,
predominantly Black high school has had a 100 percent college
acceptance rate since 1978.
Year Up to support its training and internship program for
more than 600 young adults (ages 18-26). AbbVie’s support will
enable technical skills training that is relevant and aligned with
The grants are being made by the AbbVie Foundation, a charitable
organization established and funded by AbbVie, Inc. Read the full announcement.
AbbVie is also expanding its employee matching program to $3-to-$1
for donations to civil rights nonprofits fostering racial equity.
AbbVie believes our clinical trials should reflect the populations we
serve as we aim to help patients live healthier, longer lives.
Ensuring diversity means we can better meet the needs of our patients
both today and tomorrow. We are committed to researching and bringing
treatment options for diseases that affect patients around the world,
including groups of patients who historically have been underserved.
As part of our dedication, AbbVie is committed to being an industry
leader in improving clinical research diversity. We rely on
real-world data and evidence to guide our diversity and inclusion
strategies to ensure participation in AbbVie-sponsored clinical trials
appropriately represents patients living with the diseases we are
studying. We have been and will continue to analyze our clinical
trials to ensure they reflect a diversity in race, ethnicity, age, and
gender. To this end, our continuing commitment is as follows:
- Evaluating our clinical trial protocol eligibility criteria
against real-world datasets to ensure we are designing inclusive
study protocols, enabling under-represented populations to volunteer
for our clinical trials.
- Analyzing and ensuring the age,
gender, race, and ethnicity of those enrolled in our clinical trials
appropriately reflects the age, gender, race, and ethnicity of the
patient population we are studying. If diversity gaps are identified
within indications in our portfolio, we will create a tailored plan
to address specific gaps. This plan may include enhanced community
partnerships, clinical research staff education, investigator
trainings, new site selection strategies, and targeted patient
- Routinely re-assessing clinical study demographics
to determine if our efforts to ensure participation of
under-represented populations have made an impact, pivoting to
different strategies if necessary.
- Continuing to refine our
clinical trial diversity and inclusion strategies based on analytics
and ensuring every team has access to regional indication
demographics, including AbbVie resources to help resolve previously
identified diversity gaps.
Black Americans face significant health disparities as a result of
systemic inequalities, and as a biopharmaceutical company, it is our
moral obligation to do all that we can to help reduce these
disparities. Since we became a company seven years ago, we have
developed new medicines and treatments for diseases that
disproportionately impact Black communities. This includes a cure for
Hepatitis C, as Black men and women aged 60 and older are 10 times more likely to be chronically infected
with hepatitis C compared to other Americans. We’ve also developed the
first oral medication for the management of heavy menstrual bleeding
due to uterine fibroids. Black women suffer from a higher cumulative risk of uterine
fibroids, a threefold greater incidence and relative risk of fibroids,
and an earlier age of onset. Additionally, we have developed an oral
treatment for chronic lymphocytic leukemia (CLL). Black patients with
CLL are almost twice as likely to die from a CLL-related complication in the first 5
years after diagnosis as are Caucasian patients with CLL. But we are
far from finished. We are working to develop new treatments that will
significantly advance the standard of care for a number of diseases.